



Clinical trial results:

A Phase IIIB, randomized, open-label, multicenter clinical trial to assess the immunogenicity and safety of GSK Biologicals' Herpes Zoster vaccine GSK1437173A when co-administered with Prevenar13 in adults aged 50 years and older.

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2017-001220-22 |
| Trial protocol | DE EE |
| Global end of trial date | 03 March 2020 |

Results information

| | |
|--------------------------------|-----------------|
| Result version number | v2 (current) |
| This version publication date | 21 January 2022 |
| First version publication date | 11 March 2021 |
| Version creation reason | |

Trial information

Trial identification

| | |
|-----------------------|--------|
| Sponsor protocol code | 204487 |
|-----------------------|--------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT03439657 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | GlaxoSmithKline |
| Sponsor organisation address | Rue de l'Institut 89, Rixensart, Belgium, B-1330 |
| Public contact | GSK Response Center, GlaxoSmithKline, 044 2089-904466, GSKClinicalSupportHD@gsk.com |
| Scientific contact | GSK Response Center, GlaxoSmithKline, 044 2089-904466, GSKClinicalSupportHD@gsk.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|-----------------|
| Analysis stage | Final |
| Date of interim/final analysis | 18 January 2021 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 03 March 2020 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

- To determine the vaccine response rate (VRR) to HZ/su (based on humoral immune response) one month after the second vaccine dose, when the first dose of HZ/su is co-administered with Prevenar13 (Co-Ad group).
- To demonstrate non-inferiority of the humoral immune response to two doses of HZ/su at one month after the last vaccine dose, when the first dose of HZ/su is co-administered with Prevenar13 (Co-Ad group) compared to when two doses of HZ/su are administered subsequent to Prevenar13 (Control Group).
- To demonstrate non-inferiority of the humoral immune response to Prevenar13 at one month after the vaccine dose, when Prevenar13 is co-administered with the first HZ/su dose (Co-Ad group) compared to when Prevenar13 is administered separately from HZ/su (Control group), for the 13 serotypes included in Prevenar13 analyzed sequentially.

Protection of trial subjects:

All subjects were supervised for 30 min after vaccination/product administration with appropriate medical treatment readily available. Vaccines/products were administered by qualified and trained personnel. Vaccines/products were administered only to eligible subjects that had no contraindications to any components of the vaccines/products. Subjects were followed-up for 12 months after the last vaccination/product administration.

Background therapy: -

Evidence for comparator: -

| | |
|---|---------------|
| Actual start date of recruitment | 12 April 2018 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | Canada: 362 |
| Country: Number of subjects enrolled | Estonia: 122 |
| Country: Number of subjects enrolled | Germany: 290 |
| Country: Number of subjects enrolled | United States: 139 |
| Worldwide total number of subjects | 913 |
| EEA total number of subjects | 412 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |

| | |
|--|-----|
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 536 |
| From 65 to 84 years | 368 |
| 85 years and over | 9 |

Subject disposition

Recruitment

Recruitment details:

The study was conducted in 4 countries (Canada, Estonia, Germany & United States)

Pre-assignment

Screening details:

Out of 913 subjects enrolled in the study, 1 subject violated protocol prior to randomization. 912 subjects were vaccinated and included in the Exposed Set, 901 subjects completed the study.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Blinding implementation details:

This is not applicable as there was no blinding in this study (open-label)

Arms

| | |
|------------------------------|-------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Co-Ad Group |

Arm description:

Adults aged ≥ 50 years of age who received the first dose of GSK1437173A and one dose of Prevenar13 at Day 1 and the second dose of GSK1437173A at Month 2. Both vaccines were administered intramuscularly, GSK1437173A was administered in the deltoid muscle of the non-dominant arm, while Prevenar13 was administered in the deltoid muscle of the dominant arm

| | |
|--|---|
| Arm type | Experimental |
| Investigational medicinal product name | HZ/su vaccine GSK1437173A |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection, Powder and suspension for suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

2 doses of 0.5 mL of the vaccine in a 0,2 Months schedule. Administered by intramuscular injection into the deltoid muscle of the non-dominant arm.

| | |
|--|--------------------------|
| Investigational medicinal product name | Prevenar13 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

1 dose of 0.5 mL of the vaccine. Administered by intramuscular injection into the deltoid muscle of the dominant arm.

| | |
|------------------|---------------|
| Arm title | Control Group |
|------------------|---------------|

Arm description:

Adults aged ≥ 50 years of age who received one dose of Prevenar13 at Day 1, the first dose of GSK1437173A at Month 2 and the second dose of GSK1437173A at Month 4. Both vaccines were administered intramuscularly, GSK1437173A was administered in the deltoid muscle of the non-dominant arm, while Prevenar13 was administered in the deltoid muscle of the dominant arm

| | |
|----------|---------|
| Arm type | Placebo |
|----------|---------|

| | |
|--|---|
| Investigational medicinal product name | HZ/su vaccine GSK1437173A |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection, Powder and suspension for suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

2 doses of 0.5 mL of the vaccine in a 0,2 Months schedule. Administered by intramuscular injection into the deltoid muscle of the non-dominant arm.

| | |
|--|--------------------------|
| Investigational medicinal product name | Prevenar13 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

1 dose of 0.5 mL of the vaccine. Administered by intramuscular injection into the deltoid muscle of the dominant arm.

| Number of subjects in period 1^[1] | Co-Ad Group | Control Group |
|---|-------------|---------------|
| Started | 449 | 463 |
| Completed | 442 | 459 |
| Not completed | 7 | 4 |
| Adverse event, non-fatal | 2 | 3 |
| Lost to follow-up | 1 | - |
| Consent withdrawal, not due to an Adverse Event | 3 | - |
| Protocol deviation | 1 | 1 |

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Out of 913 subjects enrolled in the study, 1 subject violated protocol. 912 subjects were vaccinated and included in the Exposed Set.

Baseline characteristics

Reporting groups

| | |
|---|---------------|
| Reporting group title | Co-Ad Group |
| Reporting group description: | |
| Adults aged ≥50 years of age who received the first dose of GSK1437173A and one dose of Prevenar13 at Day 1 and the second dose of GSK1437173A at Month 2. Both vaccines were administered intramuscularly, GSK1437173A was administered in the deltoid muscle of the non-dominant arm, while Prevenar13 was administered in the deltoid muscle of the dominant arm | |
| Reporting group title | Control Group |
| Reporting group description: | |
| Adults aged ≥50 years of age who received one dose of Prevenar13 at Day 1, the first dose of GSK1437173A at Month 2 and the second dose of GSK1437173A at Month 4. Both vaccines were administered intramuscularly, GSK1437173A was administered in the deltoid muscle of the non-dominant arm, while Prevenar13 was administered in the deltoid muscle of the dominant arm | |

| Reporting group values | Co-Ad Group | Control Group | Total |
|--|-------------|---------------|-------|
| Number of subjects | 449 | 463 | 912 |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 271 | 265 | 536 |
| From 65-84 years | 175 | 192 | 367 |
| 85 years and over | 3 | 6 | 9 |
| Age continuous | | | |
| Units: years | | | |
| arithmetic mean | 63.1 | 63.2 | |
| standard deviation | ± 8.3 | ± 8.4 | - |
| Sex: Female, Male | | | |
| Units: Participants | | | |
| Female | 259 | 284 | 543 |
| Male | 190 | 179 | 369 |
| Race/Ethnicity, Customized | | | |
| Units: Subjects | | | |
| American Indian Or Alaska Native | 1 | 0 | 1 |
| Black Or African American | 8 | 8 | 16 |
| Mixed Origin | 0 | 2 | 2 |
| White - Arabic / North African Heritage | 1 | 1 | 2 |
| White - Caucasian / European Heritage | 439 | 452 | 891 |

End points

End points reporting groups

| | |
|---|---------------|
| Reporting group title | Co-Ad Group |
| Reporting group description: | |
| Adults aged ≥ 50 years of age who received the first dose of GSK1437173A and one dose of Prevenar13 at Day 1 and the second dose of GSK1437173A at Month 2. Both vaccines were administered intramuscularly, GSK1437173A was administered in the deltoid muscle of the non-dominant arm, while Prevenar13 was administered in the deltoid muscle of the dominant arm | |
| Reporting group title | Control Group |
| Reporting group description: | |
| Adults aged ≥ 50 years of age who received one dose of Prevenar13 at Day 1, the first dose of GSK1437173A at Month 2 and the second dose of GSK1437173A at Month 4. Both vaccines were administered intramuscularly, GSK1437173A was administered in the deltoid muscle of the non-dominant arm, while Prevenar13 was administered in the deltoid muscle of the dominant arm | |

Primary: Percentage of subjects with a Vaccine response for Anti-glycoprotein E (Anti-gE) in Co-Ad Group

| | |
|---|---|
| End point title | Percentage of subjects with a Vaccine response for Anti-glycoprotein E (Anti-gE) in Co-Ad Group ^{[1][2]} |
| End point description: | |
| Vaccine response rate (VRR) for Varicella Zoster Virus (VZV) anti-glycoprotein E (gE) humoral immunogenicity was determined by Enzyme Linked Immunosorbent Assay (ELISA). The VRR for anti-gE is defined as the percentage of subjects who had at least: a 4-fold increase in the anti-gE antibodies concentration as compared to the pre-vaccination anti-gE antibodies concentration, for subjects who are seropositive at baseline, or, a 4-fold increase in the anti-gE antibodies concentration as compared to the anti-gE antibodies cut-off value for seropositivity, for subjects who are seronegative at baseline. Analysis was performed on the Per-Protocol Set (PPS) for immunogenicity that included all evaluable subjects who met all eligibility criteria, who complied with the procedures and intervals allowed for the analysis and for whom data concerning immunogenicity outcome measures were available. | |
| End point type | Primary |
| End point timeframe: | |
| One month post-dose 2 (Month 3) | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The scope of this primary endpoint was descriptive, no statistical analyses were conducted.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint only required results for the Co-Ad group.

| | | | | |
|----------------------------------|---------------------|--|--|--|
| End point values | Co-Ad Group | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 426 | | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | 99.1 (97.6 to 99.7) | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Anti-gE antibody concentrations

| | |
|-----------------|--|
| End point title | Anti-gE antibody concentrations ^[3] |
|-----------------|--|

End point description:

Anti-gE antibody concentrations in terms of Geometric Mean concentrations (GMC) were determined by ELISA and expressed as milli-international units per milliliter (mIU/mL). Analysis was performed on the PPS for immunogenicity that included all evaluable subjects who met all eligibility criteria, who complied with the procedures and intervals allowed for the analysis and for whom data concerning immunogenicity outcome measures were available.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

One month post-dose 2 (at Month 3 for the Co-Ad and Month 5 for the Control group).

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The scope of this primary endpoint was descriptive, no statistical analyses were conducted.

| End point values | Co-Ad Group | Control Group | | |
|--|---------------------------------|---------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 426 | 436 | | |
| Units: mIU/mL | | | | |
| geometric mean (confidence interval 95%) | 54789.9 (51586.3 to 58192.4) | 59126.7 (55973.8 to 62457.1) | | |

Statistical analyses

No statistical analyses for this end point

Primary: Anti-pneumococcal antibody titers

| | |
|-----------------|--|
| End point title | Anti-pneumococcal antibody titers ^[4] |
|-----------------|--|

End point description:

Anti-pneumococcal antibody titers for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) were determined by Multiplex Opsonophagocytosis Assay (MOPA). Analysis was performed on the PPS for immunogenicity that included all evaluable subjects who met all eligibility criteria, who complied with the procedures and intervals allowed for the analysis and for whom data concerning immunogenicity outcome measures were available.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

At one month post-dose 1 (Month 1)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The scope of this primary endpoint was descriptive, no statistical analyses were conducted.

| End point values | Co-Ad Group | Control Group | | |
|--|---------------------------|---------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 425 | 434 | | |
| Units: Titers | | | | |
| geometric mean (confidence interval 95%) | | | | |
| MOPA-1 [N=425,434] | 144.2 (120.5 to 172.6) | 151.5 (126.0 to 182.1) | | |
| MOPA-3 [N=425,434] | 99.8 (87.2 to 114.1) | 100.2 (88.0 to 114.1) | | |
| MOPA-4 [N=425,434] | 1127.2 (975.5 to 1302.5) | 1392.4 (1206.5 to 1607.0) | | |
| MOPA-5 [N=424,434] | 279.4 (231.2 to 337.7) | 292.8 (243.5 to 352.1) | | |
| MOPA-6A [N=425,434] | 1839.3 (1570.0 to 2154.9) | 2354.9 (2015.0 to 2752.2) | | |
| MOPA-6B [N=425,433] | 1499.4 (1241.2 to 1811.4) | 2025.9 (1715.5 to 2392.4) | | |
| MOPA-7F [N=425,434] | 1981 (1735.2 to 2261.5) | 2387.5 (2112.7 to 2698.0) | | |
| MOPA-9V [N=425,434] | 2541.9 (2219.2 to 2911.7) | 3049.3 (2693.7 to 3451.9) | | |
| MOPA-14 [N=424,432] | 1752.6 (1505.2 to 2040.6) | 2096 (1796.6 to 2445.2) | | |
| MOPA-18C [N=425,434] | 1450.3 (1262.5 to 1666.1) | 1606.6 (1402.6 to 1840.4) | | |
| MOPA-19A [N=425,434] | 1684.9 (1477.2 to 1921.9) | 1664.3 (1465.7 to 1889.7) | | |
| MOPA-19F [N=425,434] | 712 (617.1 to 821.6) | 802.4 (696.2 to 924.8) | | |
| MOPA-23F [N=425,434] | 758.1 (644.9 to 891.2) | 925.5 (782.5 to 1094.7) | | |

Statistical analyses

No statistical analyses for this end point

Primary: Adjusted Geometric Mean Concentrations (GMCs) for anti-gE antibody

| | |
|-----------------|--|
| End point title | Adjusted Geometric Mean Concentrations (GMCs) for anti-gE antibody |
|-----------------|--|

End point description:

Anti-gE antibody concentrations (GMCs) adjusted for age and baseline concentrations were determined using Analysis Of Covariance (ANCOVA) model. Adjusted GMCs were expressed in milli-international units per milliliter (mIU/mL). Analysis was performed on the PPS for immunogenicity that included all evaluable subjects who met all eligibility criteria, who complied with the procedures and intervals allowed for the analysis and for whom data concerning immunogenicity outcome measures were available.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

One month post-dose 2 (at Month 3 for the Co-Ad and Month 5 for the Control group).

| End point values | Co-Ad Group | Control Group | | |
|--|---------------------------------|---------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 426 | 435 | | |
| Units: mIU/mL | | | | |
| geometric mean (confidence interval 95%) | 54634.9 (51546.0 to 57909.0) | 58526.8 (55248.5 to 61999.7) | | |

Statistical analyses

| Statistical analysis title | Anti-gE GMCs (non-inferiority) |
|--|--------------------------------|
| Statistical analysis description: | |
| Non-inferiority comparison between Control Group and Co-Ad Group in terms of geometric mean concentrations (GMCs) for anti-gE antibodies, one month after the administration of last vaccine dose. | |
| Comparison groups | Control Group v Co-Ad Group |
| Number of subjects included in analysis | 861 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[5] |
| Method | ANCOVA |
| Parameter estimate | GMC ratio |
| Point estimate | 1.07 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.99 |
| upper limit | 1.16 |

Notes:

[5] - Upper limit (UL) of the 95% confidence interval (CI) for the anti-gE antibodies Geometric Mean Concentration (GMC) ratio between the Control group and the Co-Ad group should be <1.5.

Primary: Adjusted Geometric Mean Titers (GMTs) of anti-pneumococcal antibodies

| | |
|---|---|
| End point title | Adjusted Geometric Mean Titers (GMTs) of anti-pneumococcal antibodies |
| End point description: | |
| Geometric mean antibody (anti-pneumococcal antibodies: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) titers adjusted for age and baseline concentration were determined using ANCOVA model. Analysis was performed on the PPS for immunogenicity that included all evaluable subjects who met all eligibility criteria, who complied with the procedures and intervals allowed for the analysis and for whom data concerning immunogenicity outcome measures were available. | |
| End point type | Primary |
| End point timeframe: | |
| At one month post-dose 1 (Month 1) | |

| End point values | Co-Ad Group | Control Group | | |
|--|---------------------------|---------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 425 | 433 | | |
| Units: Titers | | | | |
| geometric mean (confidence interval 95%) | | | | |
| MOPA-1 [N=433,425] | 141.2 (118.7 to 167.9) | 147.1 (123.9 to 174.7) | | |
| MOPA-3 [N=431,425] | 97.3 (86.0 to 110.0) | 99.6 (88.1 to 112.6) | | |
| MOPA-4 [N=432,423] | 1066.9 (924.2 to 1231.5) | 1331.6 (1155.2 to 1535.0) | | |
| MOPA-5 [N=433,423] | 269.1 (225.8 to 320.8) | 278.9 (234.4 to 331.8) | | |
| MOPA-6A [N=433,424] | 1784.4 (1530.2 to 2080.8) | 2253.8 (1935.6 to 2624.3) | | |
| MOPA-6B [N=431,424] | 1445.4 (1219.3 to 1713.4) | 1967.3 (1661.5 to 2329.3) | | |
| MOPA-7F [N=432,423] | 1935.1 (1704.3 to 2197.1) | 2337.3 (2061.2 to 2650.5) | | |
| MOPA-9V [N=431,420] | 2553.5 (2244.2 to 2905.4) | 2955.8 (2601.9 to 3357.9) | | |
| MOPA-14 [N=430,423] | 1730.7 (1491.3 to 2008.5) | 1992.3 (1718.5 to 2309.7) | | |
| MOPA-18C [N=433,423] | 1403.8 (1226.4 to 1606.8) | 1558.9 (1363.9 to 1781.9) | | |
| MOPA-19A [N=431,425] | 1619.2 (1433.7 to 1828.7) | 1663.5 (1474.0 to 1877.2) | | |
| MOPA-19F [N=433,424] | 696.4 (608.2 to 797.3) | 760.2 (664.8 to 869.2) | | |
| MOPA-23F [N=432,425] | 748.2 (637.6 to 878.0) | 896.6 (765.0 to 1050.9) | | |

Statistical analyses

| | |
|---|-----------------------------------|
| Statistical analysis title | Anti-pneumococcal antibody titers |
| Statistical analysis description: | |
| Non-inferiority comparison between Control Group and Co-Ad Group in terms of geometric mean titers (GMTs) for anti-pneumococcal antibody (MOPA-1), one month after the administration of Prevnar 13 vaccine dose. | |
| Comparison groups | Control Group v Co-Ad Group |
| Number of subjects included in analysis | 858 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[6] |
| Method | ANCOVA |
| Parameter estimate | GMT ratio |
| Point estimate | 1.04 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.82 |
| upper limit | 1.33 |

Notes:

[6] - Upper limit (UL) of 95% CI for each individual pneumococcal conjugate serotype Geometric Mean Titer (GMT) ratio of the Control group over the Co-Ad group should be <2.

| | |
|-----------------------------------|-----------------------------------|
| Statistical analysis title | Anti-pneumococcal antibody titers |
|-----------------------------------|-----------------------------------|

Statistical analysis description:

Non-inferiority comparison between Control Group and Co-Ad Group in terms of geometric mean titers (GMTs) for anti-pneumococcal antibody (MOPA-3), one month after the administration of Prevnar 13 vaccine dose.

| | |
|---|--------------------------------|
| Comparison groups | Co-Ad Group v Control Group |
| Number of subjects included in analysis | 858 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[7] |
| Method | ANCOVA |
| Parameter estimate | GMT ratio |
| Point estimate | 1.02 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.86 |
| upper limit | 1.22 |

Notes:

[7] - Upper limit (UL) of 95% CI for each individual pneumococcal conjugate serotype Geometric Mean Titer (GMT) ratio of the Control group over the Co-Ad group should be <2.

| | |
|-----------------------------------|-----------------------------------|
| Statistical analysis title | Anti-pneumococcal antibody titers |
|-----------------------------------|-----------------------------------|

Statistical analysis description:

Non-inferiority comparison between Control Group and Co-Ad Group in terms of geometric mean titers (GMTs) for anti-pneumococcal antibody (MOPA-4), one month after the administration of Prevnar 13 vaccine dose.

| | |
|---|--------------------------------|
| Comparison groups | Co-Ad Group v Control Group |
| Number of subjects included in analysis | 858 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[8] |
| Method | ANCOVA |
| Parameter estimate | GMT ratio |
| Point estimate | 1.25 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 1.02 |
| upper limit | 1.52 |

Notes:

[8] - Upper limit (UL) of 95% CI for each individual pneumococcal conjugate serotype Geometric Mean Titer (GMT) ratio of the Control group over the Co-Ad group should be <2.

| | |
|-----------------------------------|-----------------------------------|
| Statistical analysis title | Anti-pneumococcal antibody titers |
|-----------------------------------|-----------------------------------|

Statistical analysis description:

Non-inferiority comparison between Control Group and Co-Ad Group in terms of geometric mean titers

(GMTs) for anti-pneumococcal antibody (MOPA-5), one month after the administration of Prevnar 13 vaccine dose.

| | |
|---|--------------------------------|
| Comparison groups | Co-Ad Group v Control Group |
| Number of subjects included in analysis | 858 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[9] |
| Method | ANCOVA |
| Parameter estimate | GMT ratio |
| Point estimate | 1.04 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.81 |
| upper limit | 1.32 |

Notes:

[9] - Upper limit (UL) of 95% CI for each individual pneumococcal conjugate serotype Geometric Mean Titer (GMT) ratio of the Control group over the Co-Ad group should be <2.

| | |
|-----------------------------------|-----------------------------------|
| Statistical analysis title | Anti-pneumococcal antibody titers |
|-----------------------------------|-----------------------------------|

Statistical analysis description:

Non-inferiority comparison between Control Group and Co-Ad Group in terms of geometric mean titers (GMTs) for anti-pneumococcal antibody (MOPA-6B), one month after the administration of Prevnar 13 vaccine dose.

| | |
|---|---------------------------------|
| Comparison groups | Co-Ad Group v Control Group |
| Number of subjects included in analysis | 858 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[10] |
| Method | ANCOVA |
| Parameter estimate | GMT ratio |
| Point estimate | 1.36 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 1.07 |
| upper limit | 1.73 |

Notes:

[10] - Upper limit (UL) of 95% CI for each individual pneumococcal conjugate serotype Geometric Mean Titer (GMT) ratio of the Control group over the Co-Ad group should be <2.

| | |
|-----------------------------------|-----------------------------------|
| Statistical analysis title | Anti-pneumococcal antibody titers |
|-----------------------------------|-----------------------------------|

Statistical analysis description:

Non-inferiority comparison between Control Group and Co-Ad Group in terms of geometric mean titers (GMTs) for anti-pneumococcal antibody (MOPA-6A), one month after the administration of Prevnar 13 vaccine dose.

| | |
|---|---------------------------------|
| Comparison groups | Co-Ad Group v Control Group |
| Number of subjects included in analysis | 858 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[11] |
| Method | ANCOVA |
| Parameter estimate | GMT ratio |
| Point estimate | 1.26 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 1.02 |
| upper limit | 1.56 |

Notes:

[11] - Upper limit (UL) of 95% CI for each individual pneumococcal conjugate serotype Geometric Mean Titer (GMT) ratio of the Control group over the Co-Ad group should be <2.

| | |
|-----------------------------------|-----------------------------------|
| Statistical analysis title | Anti-pneumococcal antibody titers |
|-----------------------------------|-----------------------------------|

Statistical analysis description:

Non-inferiority comparison between Control Group and Co-Ad Group in terms of geometric mean titers (GMTs) for anti-pneumococcal antibody (MOPA-7F), one month after the administration of Prevnar 13 vaccine dose.

| | |
|---|---------------------------------|
| Comparison groups | Co-Ad Group v Control Group |
| Number of subjects included in analysis | 858 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[12] |
| Method | ANCOVA |
| Parameter estimate | GMT ratio |
| Point estimate | 1.21 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 1.01 |
| upper limit | 1.44 |

Notes:

[12] - Upper limit (UL) of 95% CI for each individual pneumococcal conjugate serotype Geometric Mean Titer (GMT) ratio of the Control group over the Co-Ad group should be <2.

| | |
|-----------------------------------|-----------------------------------|
| Statistical analysis title | Anti-pneumococcal antibody titers |
|-----------------------------------|-----------------------------------|

Statistical analysis description:

Non-inferiority comparison between Control Group and Co-Ad Group in terms of geometric mean titers (GMTs) for anti-pneumococcal antibody (MOPA-9V), one month after the administration of Prevnar 13 vaccine dose.

| | |
|---|---------------------------------|
| Comparison groups | Co-Ad Group v Control Group |
| Number of subjects included in analysis | 858 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[13] |
| Method | ANCOVA |
| Parameter estimate | GMT ratio |
| Point estimate | 1.16 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.97 |
| upper limit | 1.39 |

Notes:

[13] - Upper limit (UL) of 95% CI for each individual pneumococcal conjugate serotype Geometric Mean Titer (GMT) ratio of the Control group over the Co-Ad group should be <2.

| | |
|-----------------------------------|-----------------------------------|
| Statistical analysis title | Anti-pneumococcal antibody titers |
|-----------------------------------|-----------------------------------|

Statistical analysis description:

Non-inferiority comparison between Control Group and Co-Ad Group in terms of geometric mean titers

(GMTs) for anti-pneumococcal antibody (MOPA-14), one month after the administration of Prevnar 13 vaccine dose.

| | |
|---|---------------------------------|
| Comparison groups | Co-Ad Group v Control Group |
| Number of subjects included in analysis | 858 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[14] |
| Method | ANCOVA |
| Parameter estimate | GMT ratio |
| Point estimate | 1.15 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.94 |
| upper limit | 1.42 |

Notes:

[14] - Upper limit (UL) of 95% CI for each individual pneumococcal conjugate serotype Geometric Mean Titer (GMT) ratio of the Control group over the Co-Ad group should be <2.

| | |
|-----------------------------------|-----------------------------------|
| Statistical analysis title | Anti-pneumococcal antibody titers |
|-----------------------------------|-----------------------------------|

Statistical analysis description:

Non-inferiority comparison between Control Group and Co-Ad Group in terms of geometric mean titers (GMTs) for anti-pneumococcal antibody (MOPA-18C), one month after the administration of Prevnar 13 vaccine dose.

| | |
|---|---------------------------------|
| Comparison groups | Co-Ad Group v Control Group |
| Number of subjects included in analysis | 858 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[15] |
| Method | ANCOVA |
| Parameter estimate | GMT ratio |
| Point estimate | 1.11 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.92 |
| upper limit | 1.34 |

Notes:

[15] - Upper limit (UL) of 95% CI for each individual pneumococcal conjugate serotype Geometric Mean Titer (GMT) ratio of the Control group over the Co-Ad group should be <2.

| | |
|-----------------------------------|-----------------------------------|
| Statistical analysis title | Anti-pneumococcal antibody titers |
|-----------------------------------|-----------------------------------|

Statistical analysis description:

Non-inferiority comparison between Control Group and Co-Ad Group in terms of geometric mean titers (GMTs) for anti-pneumococcal antibody (MOPA-19A), one month after the administration of Prevnar 13 vaccine dose.

| | |
|---|---------------------------------|
| Comparison groups | Control Group v Co-Ad Group |
| Number of subjects included in analysis | 858 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[16] |
| Method | ANCOVA |
| Parameter estimate | GMT ratio |
| Point estimate | 1.03 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.87 |
| upper limit | 1.22 |

Notes:

[16] - Upper limit (UL) of 95% CI for each individual pneumococcal conjugate serotype Geometric Mean Titer (GMT) ratio of the Control group over the Co-Ad group should be <2.

| | |
|-----------------------------------|-----------------------------------|
| Statistical analysis title | Anti-pneumococcal antibody titers |
|-----------------------------------|-----------------------------------|

Statistical analysis description:

Non-inferiority comparison between Control Group and Co-Ad Group in terms of geometric mean titers (GMTs) for anti-pneumococcal antibody (MOPA-19F), one month after the administration of Prevnar 13 vaccine dose.

| | |
|---|---------------------------------|
| Comparison groups | Control Group v Co-Ad Group |
| Number of subjects included in analysis | 858 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[17] |
| Method | ANCOVA |
| Parameter estimate | GMT ratio |
| Point estimate | 1.09 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.9 |
| upper limit | 1.32 |

Notes:

[17] - Upper limit (UL) of 95% CI for each individual pneumococcal conjugate serotype Geometric Mean Titer (GMT) ratio of the Control group over the Co-Ad group should be <2.

| | |
|-----------------------------------|-----------------------------------|
| Statistical analysis title | Anti-pneumococcal antibody titers |
|-----------------------------------|-----------------------------------|

Statistical analysis description:

Non-inferiority comparison between Control Group and Co-Ad Group in terms of geometric mean titers (GMTs) for anti-pneumococcal antibody (MOPA-23F), one month after the administration of Prevnar 13 vaccine dose.

| | |
|---|---------------------------------|
| Comparison groups | Control Group v Co-Ad Group |
| Number of subjects included in analysis | 858 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority ^[18] |
| Method | ANCOVA |
| Parameter estimate | GMT ratio |
| Point estimate | 1.2 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.96 |
| upper limit | 1.5 |

Notes:

[18] - Upper limit (UL) of 95% CI for each individual pneumococcal conjugate serotype Geometric Mean Titer (GMT) ratio of the Control group over the Co-Ad group should be <2.

Secondary: Number of subjects with any and grade 3 solicited local symptoms by vaccine and dose

| | |
|-----------------|---|
| End point title | Number of subjects with any and grade 3 solicited local |
|-----------------|---|

End point description:

Assessed solicited local symptoms were pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 erythema/swelling = erythema/swelling that had spread beyond 100 millimeters (mm) of injection site. The Co-Ad Group received only 2 vaccine doses. Analysis was performed on Exposed Set (ES) which included all subjects with at least one vaccine administration documented and who provided solicited safety data.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Within 7 days (Day 1 - 7) after each vaccination

| End point values | Co-Ad Group | Control Group | | |
|--|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 447 | 463 | | |
| Units: Participants | | | | |
| Any Erythema, GSK1437173A, Dose1 [N=447,0] | 120 | 0 | | |
| Grade3 Erythema, GSK1437173A, Dose1 [N=447,0] | 5 | 0 | | |
| Any Erythema, Prevenar13, Dose1 [N=447,463] | 48 | 31 | | |
| Grade3 Erythema, Prevenar13, Dose1 [N=447,463] | 2 | 1 | | |
| Any Pain, GSK1437173A, Dose1 [N=447,0] | 332 | 0 | | |
| Grade3 Pain, GSK1437173A, Dose1 [N=447,0] | 25 | 0 | | |
| Any Pain, Prevenar13, Dose1 [N=447,463] | 233 | 241 | | |
| Grade3 Pain, Prevenar13, Dose1 [N=447,463] | 11 | 9 | | |
| Any Swelling, GSK1437173A, Dose1 [N=447,0] | 69 | 0 | | |
| Grade3 Swelling, GSK1437173A, Dose1 [N=447,0] | 0 | 0 | | |
| Any Swelling, Prevenar13, Dose1 [N=447,463] | 33 | 21 | | |
| Grade3 Swelling, Prevenar13, Dose1 [N=447,463] | 1 | 0 | | |
| Any Erythema, GSK1437173A, Dose2 [N=444,458] | 147 | 128 | | |
| Grade3 Erythema, GSK1437173A, Dose2 [N=444,458] | 9 | 5 | | |
| Any Pain, GSK1437173A, Dose2 [N=444,458] | 326 | 359 | | |
| Grade3 Pain, GSK1437173A, Dose2 [N=444,458] | 28 | 32 | | |
| Any Swelling, GSK1437173A, Dose2 [N=444,458] | 70 | 72 | | |
| Grade3 Swelling, GSK1437173A, Dose2 [N=444,458] | 1 | 2 | | |
| Any Erythema, GSK1437173A, Dose3 [N=0,459] | 0 | 123 | | |
| Grade3 Erythema, GSK1437173A, Dose3 [N=0,459] | 0 | 1 | | |

| | | | | |
|--|---|-----|--|--|
| Any Pain, GSK1437173A, Dose3 [N=0,459] | 0 | 350 | | |
| Grade3 Pain, GSK1437173A, Dose3 [N=0,459] | 0 | 41 | | |
| Any Swelling, GSK1437173A, Dose3 [N=0,459] | 0 | 60 | | |
| Grade3 Swelling, GSK1437173A, Dose3 [N=0,459] | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of days with each solicited local symptoms

| | |
|---|---|
| End point title | Number of days with each solicited local symptoms |
| End point description: The number of days with any local symptoms had been assessed during the post-vaccination period. Analysis was performed on ES which included all subjects with at least one vaccine administration documented and who provided solicited safety data and for those who experienced the specified symptom for the specific dose. | |
| End point type | Secondary |
| End point timeframe: Within 7 days (Day 1 - 7) after each vaccination | |

| End point values | Co-Ad Group | Control Group | | |
|---------------------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 347 | 359 | | |
| Units: Days | | | | |
| median (inter-quartile range (Q1-Q3)) | | | | |
| Any erythema,Dose1 [N=131,31] | 3 (2 to 5) | 2 (1 to 4) | | |
| Any pain,Dose1 [N=347,241] | 3 (2 to 4) | 2 (1 to 2) | | |
| Any swelling, Dose1 [N=76,21] | 2 (2 to 4) | 2 (1 to 3) | | |
| Any erythema, Dose2 [N=147,128] | 3 (2 to 4) | 2 (2 to 4) | | |
| Any pain,Dose2 [N=326,359] | 3 (2 to 4) | 3 (2 to 4) | | |
| Any swelling, Dose2 [N=70,72] | 3 (2 to 4) | 2 (1.5 to 4) | | |
| Any erythema,Dose3 [N=0,123] | 0 (0 to 0) | 2 (2 to 3) | | |
| Any pain,Dose3 [N=0,350] | 0 (0 to 0) | 3 (2 to 3) | | |
| Any swelling,Dose3 [N=0,60] | 0 (0 to 0) | 2 (1 to 4) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with any, Grade 3 and related solicited general symptoms

| | |
|-----------------|--|
| End point title | Number of subjects with any, Grade 3 and related solicited |
|-----------------|--|

End point description:

Assessed solicited general symptoms were fatigue, fever [defined as oral temperature ≥ 38.0 degrees Celsius ($^{\circ}\text{C}$)/ 100.4 degrees Fahrenheit ($^{\circ}\text{F}$)], GastroIntestinal (GI) symptoms, headache, myalgia and shivering. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.0 $^{\circ}\text{C}$. Related = symptom assessed by the investigator as related to the vaccination. Analysis was performed on ES which included all subjects with at least one vaccine administration documented and who provided solicited safety data.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Within 7 days (Day 1 - 7) after each vaccination

| End point values | Co-Ad Group | Control Group | | |
|--|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 448 | 463 | | |
| Units: Participants | | | | |
| Any Fatigue, Dose1 [N=448,463] | 166 | 85 | | |
| Grade3 Fatigue, Dose1 [N=448,463] | 21 | 5 | | |
| Related Fatigue, Dose1 [N=448,463] | 149 | 67 | | |
| Any Fever, Dose1 [N=448,463] | 10 | 2 | | |
| Grade3 Fever, Dose1 [N=448,463] | 1 | 0 | | |
| Related Fever, Dose1 [N=448,463] | 8 | 0 | | |
| Any GI symptoms, Dose1 [N=448,463] | 61 | 37 | | |
| Grade3 GI symptoms, Dose1 [N=448,463] | 6 | 1 | | |
| Related GI symptoms, Dose1 [N=448,463] | 55 | 30 | | |
| Any Headache, Dose1 [N=448,463] | 130 | 72 | | |
| Grade3 Headache, Dose1 [N=448,463] | 10 | 0 | | |
| Related Headache, Dose1 [N=448,463] | 113 | 59 | | |
| Any Myalgia, Dose1 [N=448,463] | 168 | 102 | | |
| Grade3 Myalgia, Dose1 [N=448,463] | 17 | 4 | | |
| Related Myalgia, Dose1 [N=448,463] | 150 | 86 | | |
| Any Shivering, Dose1 [N=448,463] | 78 | 7 | | |
| Grade3 Shivering, Dose1 [N=448,463] | 9 | 0 | | |
| Related Shivering, Dose1 [N=448,463] | 71 | 7 | | |
| Any Fatigue, Dose2 [N=444,458] | 192 | 152 | | |
| Grade3 Fatigue, Dose2 [N=444,458] | 22 | 17 | | |
| Related Fatigue, Dose2 [N=444,458] | 177 | 141 | | |
| Any Fever, Dose2 [N=444,458] | 16 | 7 | | |
| Grade3 Fever, Dose2 [N=444,458] | 2 | 2 | | |
| Related Fever, Dose2 [N=444,458] | 10 | 2 | | |
| Any GI symptoms, Dose2 [N=444,458] | 57 | 47 | | |
| Grade3 GI symptoms, Dose2 [N=444,458] | 8 | 4 | | |
| Related GI symptoms, Dose2 [N=444,458] | 50 | 44 | | |
| Any Headache, Dose2 [N=444,458] | 156 | 115 | | |
| Grade3 Headache, Dose2 [N=444,458] | 18 | 7 | | |
| Related Headache, Dose2 [N=444,458] | 143 | 99 | | |
| Any Myalgia, Dose2 [N=444,458] | 203 | 174 | | |

| | | | | |
|--------------------------------------|-----|-----|--|--|
| Grade3 Myalgia, Dose2 [N=444,458] | 23 | 24 | | |
| Related Myalgia, Dose2 [N=444,458] | 186 | 163 | | |
| Any Shivering, Dose2 [N=444,458] | 95 | 50 | | |
| Grade3 Shivering, Dose2 [N=444,458] | 12 | 8 | | |
| Related Shivering, Dose2 [N=444,458] | 86 | 47 | | |
| Any Fatigue, Dose3 [N=0,459] | 0 | 210 | | |
| Grade3 Fatigue, Dose3 [N=0,459] | 0 | 27 | | |
| Related Fatigue, Dose3 [N=0,459] | 0 | 202 | | |
| Any Fever, Dose3 [N=0,459] | 0 | 23 | | |
| Grade3 Fever, Dose3 [N=0,459] | 0 | 2 | | |
| Related Fever, Dose3 [N=0,459] | 0 | 17 | | |
| Any GI symptoms, Dose3 [N=0,459] | 0 | 69 | | |
| Grade3 GI symptoms, Dose3 [N=0,459] | 0 | 3 | | |
| Related GI symptoms, Dose3 [N=0,459] | 0 | 63 | | |
| Any Headache, Dose3 [N=0,459] | 0 | 180 | | |
| Grade3 Headache, Dose3 [N=0,459] | 0 | 23 | | |
| Related Headache, Dose3 [N=0,459] | 0 | 168 | | |
| Any Myalgia, Dose3 [N=0,459] | 0 | 224 | | |
| Grade3 Myalgia, Dose3 [N=0,459] | 0 | 37 | | |
| Related Myalgia, Dose3 [N=0,459] | 0 | 215 | | |
| Any Shivering, Dose3 [N=0,459] | 0 | 122 | | |
| Grade3 Shivering, Dose3 [N=0,459] | 0 | 20 | | |
| Related Shivering, Dose3 [N=0,459] | 0 | 117 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of days with solicited general symptoms

| | |
|---|--|
| End point title | Number of days with solicited general symptoms |
| End point description: | |
| The number of days with any general symptoms had been assessed during the post-vaccination period. Assessed solicited general symptoms were fatigue, fever, GastroIntestinal (GI) symptoms, headache, myalgia and shivering. Analysis was performed on ES which included all subjects with at least one vaccine administration documented and who provided solicited safety data and for those who experienced the specified symptom for the specific dose. | |
| End point type | Secondary |
| End point timeframe: | |
| Within 7 days (Day 1 - 7) after each vaccination | |

| End point values | Co-Ad Group | Control Group | | |
|---------------------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 203 | 224 | | |
| Units: Days | | | | |
| median (inter-quartile range (Q1-Q3)) | | | | |
| Any fatigue,Dose1 [N=166,85] | 2 (1 to 3) | 2 (1 to 3) | | |
| Any GI symptoms,Dose1 [N=61,37] | 2 (1 to 2) | 1 (1 to 2) | | |

| | | | | |
|---------------------------------|------------|--------------|--|--|
| Any headache,Dose1 [N=130,72] | 2 (1 to 3) | 1 (1 to 2) | | |
| Any myalgia,Dose1 [N=168,102] | 2 (1 to 3) | 2 (1 to 3) | | |
| Any shivering,Dose1 [N=78,7] | 1 (1 to 2) | 1 (1 to 3) | | |
| Any fever,Dose1 [N=10,2] | 1 (1 to 1) | 1 (1 to 1) | | |
| Any fatigue,Dose2 [N=192,152] | 2 (1 to 3) | 2 (1 to 3) | | |
| Any GI symptoms,Dose2 [N=57,47] | 1 (1 to 2) | 1 (1 to 2) | | |
| Any headache,Dose2 [N=156,115] | 2 (1 to 3) | 2 (1 to 3) | | |
| Any myalgia,Dose2 [N=203,174] | 2 (1 to 3) | 2 (1 to 3) | | |
| Any shivering,Dose2 [N=95,50] | 1 (1 to 2) | 1 (1 to 2) | | |
| Any fever,Dose2 [N=16,7] | 1 (1 to 1) | 1 (1 to 3) | | |
| Any fatigue,Dose3 [N=0,210] | 0 (0 to 0) | 2 (1 to 3) | | |
| Any GI symptoms,Dose3 [N=0,69] | 0 (0 to 0) | 1 (1 to 2) | | |
| Any headache,Dose3 [N=0,180] | 0 (0 to 0) | 1.5 (1 to 2) | | |
| Any myalgia,Dose3 [N=0,224] | 0 (0 to 0) | 2 (1 to 3) | | |
| Any shivering,Dose3 [N=0,122] | 0 (0 to 0) | 1 (1 to 2) | | |
| Any fever,Dose3 [N=0,23] | 0 (0 to 0) | 1 (1 to 1) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with any, Grade 3 and related unsolicited Adverse Events (AE)

| | |
|-----------------|--|
| End point title | Number of subjects with any, Grade 3 and related unsolicited Adverse Events (AE) |
|-----------------|--|

End point description:

An unsolicited AE covered any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination. Analysis was performed on ES which included all subjects with at least one vaccine administered.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Within 30 days (Day 1 to 30) after each vaccination

| End point values | Co-Ad Group | Control Group | | |
|-----------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 449 | 463 | | |
| Units: Participants | | | | |
| Subjects with any AEs | 95 | 107 | | |
| Subjects with Grade 3 AEs | 9 | 13 | | |
| Subjects with related AEs | 35 | 25 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with any and related Serious Adverse Events (SAE) from Day 1 to 30 days post last vaccination

| | |
|--|--|
| End point title | Number of subjects with any and related Serious Adverse Events (SAE) from Day 1 to 30 days post last vaccination |
| End point description: SAEs assessed included medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity. Related SAEs= SAEs assessed by the investigator as causally related to the study vaccination. Analysis was performed on ES which included all subjects with at least one vaccine administered. | |
| End point type | Secondary |
| End point timeframe: From first vaccination at Day 1 up to 30 days post last vaccination | |

| End point values | Co-Ad Group | Control Group | | |
|-----------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 449 | 463 | | |
| Units: Participants | | | | |
| Subjects with any SAEs | 7 | 8 | | |
| Subjects with related SAEs | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with any and related SAEs from 30 days post last vaccination up to study end.

| | |
|---|--|
| End point title | Number of subjects with any and related SAEs from 30 days post last vaccination up to study end. |
| End point description: Serious adverse events (SAEs) assessed included medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity. Related SAEs= SAEs assessed by the investigator as causally related to the study vaccination. Analysis was performed on ES which included all subjects with at least one vaccine administered. | |
| End point type | Secondary |
| End point timeframe: From 30 days post last vaccination up to study end (Month 14 for the Co-Ad group and Month 16 for the Control group) | |

| End point values | Co-Ad Group | Control Group | | |
|-----------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 449 | 463 | | |
| Units: Participants | | | | |
| Subjects with any SAEs | 10 | 10 | | |
| Subjects with related SAEs | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with any and related Potential immune-mediated diseases (pIMDs) from Day 1 to 30 days post last vaccination

| | |
|-----------------|--|
| End point title | Number of subjects with any and related Potential immune-mediated diseases (pIMDs) from Day 1 to 30 days post last vaccination |
|-----------------|--|

End point description:

pIMDs assessed were a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which might or might not had an autoimmune aetiology. Related pIMDs= pIMDs assessed by the investigator as causally related to the study vaccination. Analysis was performed on ES which included all subjects with at least one vaccine administered.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From first vaccination at Day 1 up to 30 days post last vaccination.

| End point values | Co-Ad Group | Control Group | | |
|-----------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 449 | 463 | | |
| Units: Participants | | | | |
| Subjects with any pIMDs | 1 | 1 | | |
| Subjects with related pIMDs | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with any pIMDs from 30 days post last vaccination up to study end.

| | |
|-----------------|---|
| End point title | Number of subjects with any pIMDs from 30 days post last vaccination up to study end. |
|-----------------|---|

End point description:

pIMDs assessed were a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which might or might not had an autoimmune aetiology. Analysis was performed on ES which included all subjects with at least one vaccine administered.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From 30 days post last vaccination up to study end (Month 14 for the Co-Ad group and Month 16 for the Control group)

| End point values | Co-Ad Group | Control Group | | |
|-----------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 449 | 463 | | |
| Units: Participants | 1 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with any and Grade 3 solicited local symptoms by dose

| | |
|-----------------|--|
| End point title | Number of subjects with any and Grade 3 solicited local symptoms by dose |
|-----------------|--|

End point description:

Assessed solicited local symptoms were pain, erythema and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 erythema/swelling = erythema/swelling that had spread beyond 100 millimeters (mm) of injection site. The Co-Ad Group received only 2 vaccine doses. Analysis was performed on Exposed Set (ES) which included all subjects with at least one vaccine administration documented and who provided solicited safety data.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Within 7 days (Day 1 - 7) after each vaccination

| End point values | Co-Ad Group | Control Group | | |
|------------------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 448 | 463 | | |
| Units: Participants | | | | |
| Any Erythema, Dose1 [N=448,463] | 131 | 31 | | |
| Grade3 Erythema, Dose1 [N=448,463] | 7 | 1 | | |
| Any Pain, Dose1 [N=448,463] | 347 | 241 | | |
| Grade3 Pain, Dose1 [N=448,463] | 28 | 9 | | |
| Any Swelling, Dose1 [N=448,463] | 76 | 21 | | |
| Grade3 Swelling, Dose1 [N=448,463] | 1 | 0 | | |
| Any Erythema, Dose2 [N=444,458] | 147 | 128 | | |
| Grade3 Erythema, Dose2 [N=444,458] | 9 | 5 | | |
| Any Pain, Dose2 [N=444,458] | 326 | 359 | | |
| Grade3 Pain, Dose2 [N=444,458] | 28 | 32 | | |
| Any Swelling, Dose2 [N=444,458] | 70 | 72 | | |
| Grade3 Swelling, Dose2 [N=444,458] | 1 | 2 | | |
| Any Erythema, Dose3 [N=0,459] | 0 | 123 | | |

| | | | | |
|----------------------------------|---|-----|--|--|
| Grade3 Erythema, Dose3 [N=0,459] | 0 | 1 | | |
| Any Pain, Dose3 [N=0,459] | 0 | 350 | | |
| Grade3 Pain, Dose3 [N=0,459] | 0 | 41 | | |
| Any Swelling, Dose3 [N=0,459] | 0 | 60 | | |
| Grade3 Swelling, Dose3 [N=0,459] | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Solicited AEs: During the 7-day (Days 1 to 7) after each vaccination, Unsolicited AEs: During the 30 day (Days 1 to 30) after any vaccination, SAEs: throughout the study period [Day 1 to study end (Month 14 for Co-Ad group and Month-16 for Control Group)]

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 23.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|---------------|
| Reporting group title | Control Group |
|-----------------------|---------------|

Reporting group description:

Adults aged ≥ 50 years of age who received one dose of Prevenar13 at Day 1, the first dose of GSK1437173A at Month 2 and the second dose of GSK1437173A at Month 4. Both vaccines were administered intramuscularly, GSK1437173A was administered in the deltoid muscle of the non-dominant arm, while Prevenar13 was administered in the deltoid muscle of the dominant arm

| | |
|-----------------------|-------------|
| Reporting group title | Co-Ad Group |
|-----------------------|-------------|

Reporting group description:

Adults aged ≥ 50 years of age who received the first dose of GSK1437173A and one dose of Prevenar13 at Day 1 and the second dose of GSK1437173A at Month 2. Both vaccines were administered intramuscularly, GSK1437173A was administered in the deltoid muscle of the non-dominant arm, while Prevenar13 was administered in the deltoid muscle of the dominant arm

| Serious adverse events | Control Group | Co-Ad Group | |
|---|------------------|------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 16 / 463 (3.46%) | 16 / 449 (3.56%) | |
| number of deaths (all causes) | 4 | 2 | |
| number of deaths resulting from adverse events | | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Endometrial adenocarcinoma | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lung cancer metastatic | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lung neoplasm | | | |

| | | | |
|--|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Metastatic carcinoma of the bladder | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Neoplasm malignant | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Monoclonal gammopathy | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Plasma cell myeloma | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular disorders | | | |
| Peripheral arterial occlusive disease | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Multiple organ dysfunction syndrome | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Reproductive system and breast disorders | | | |
| Ovarian cyst | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Pneumothorax | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Asthma | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injury, poisoning and procedural complications | | | |
| Road traffic accident | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Congenital, familial and genetic disorders | | | |
| Hypertrophic cardiomyopathy | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |
| Acute myocardial infarction | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Angina pectoris | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Angina unstable | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac failure chronic | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Coronary artery disease | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 2 / 449 (0.45%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dressler's syndrome | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypertensive heart disease | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myocardial infarction | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pericardial effusion | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pericarditis | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Stress cardiomyopathy | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ventricular fibrillation | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Nervous system disorders | | | |
| Cerebral haematoma | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Inguinal hernia | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oesophagitis | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Volvulus | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatobiliary disorders | | | |
| Cholelithiasis | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal and urinary disorders | | | |
| Nephrotic syndrome | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Intervertebral disc protrusion | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Appendicitis | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diverticulitis | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Escherichia bacteraemia | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peritonitis | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyelonephritis acute | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sepsis | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | Control Group | Co-Ad Group | |
|---|--------------------|--------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 427 / 463 (92.22%) | 419 / 449 (93.32%) | |
| Vascular disorders | | | |
| Aortic stenosis | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences (all) | 0 | 1 | |
| Hypertension | | | |
| subjects affected / exposed | 5 / 463 (1.08%) | 3 / 449 (0.67%) | |
| occurrences (all) | 5 | 3 | |
| Circulatory collapse | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Lymphoedema | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| General disorders and administration | | | |

| | | | |
|------------------------------------|--------------------|--------------------|--|
| site conditions | | | |
| Administration site pruritus | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Asthenia | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Feeling hot | | | |
| subjects affected / exposed | 2 / 463 (0.43%) | 2 / 449 (0.45%) | |
| occurrences (all) | 2 | 2 | |
| Fatigue | | | |
| subjects affected / exposed | 261 / 463 (56.37%) | 243 / 449 (54.12%) | |
| occurrences (all) | 448 | 361 | |
| Chills | | | |
| subjects affected / exposed | 143 / 463 (30.89%) | 139 / 449 (30.96%) | |
| occurrences (all) | 179 | 174 | |
| Chest pain | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 2 / 449 (0.45%) | |
| occurrences (all) | 0 | 2 | |
| Axillary pain | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 2 / 449 (0.45%) | |
| occurrences (all) | 0 | 2 | |
| Injection site bruising | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences (all) | 0 | 1 | |
| Injection site erythema | | | |
| subjects affected / exposed | 190 / 463 (41.04%) | 192 / 449 (42.76%) | |
| occurrences (all) | 286 | 278 | |
| Injection site hypoaesthesia | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Injection site movement impairment | | | |

| | | |
|-----------------------------|--------------------|--------------------|
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) |
| occurrences (all) | 1 | 0 |
| Injection site oedema | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) |
| occurrences (all) | 1 | 0 |
| Injection site pain | | |
| subjects affected / exposed | 406 / 463 (87.69%) | 389 / 449 (86.64%) |
| occurrences (all) | 952 | 673 |
| Injection site pruritus | | |
| subjects affected / exposed | 7 / 463 (1.51%) | 7 / 449 (1.56%) |
| occurrences (all) | 10 | 9 |
| Injection site rash | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 2 / 449 (0.45%) |
| occurrences (all) | 0 | 2 |
| Injection site reaction | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 1 / 449 (0.22%) |
| occurrences (all) | 1 | 1 |
| Injection site swelling | | |
| subjects affected / exposed | 117 / 463 (25.27%) | 108 / 449 (24.05%) |
| occurrences (all) | 156 | 146 |
| Injection site warmth | | |
| subjects affected / exposed | 2 / 463 (0.43%) | 1 / 449 (0.22%) |
| occurrences (all) | 2 | 1 |
| Peripheral swelling | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 2 / 449 (0.45%) |
| occurrences (all) | 0 | 2 |
| Pain | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) |
| occurrences (all) | 1 | 0 |
| Oedema peripheral | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 2 / 449 (0.45%) |
| occurrences (all) | 0 | 2 |
| Non-cardiac chest pain | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) |
| occurrences (all) | 0 | 1 |
| Malaise | | |

| | | | |
|---|------------------------|------------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 463 (0.00%) 0 | 2 / 449 (0.45%) 2 | |
| Pyrexia subjects affected / exposed occurrences (all) | 29 / 463 (6.26%) 32 | 23 / 449 (5.12%) 26 | |
| Sensation of foreign body subjects affected / exposed occurrences (all) | 0 / 463 (0.00%) 0 | 1 / 449 (0.22%) 1 | |
| Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all) | 0 / 463 (0.00%) 0 | 2 / 449 (0.45%) 2 | |
| Seasonal allergy subjects affected / exposed occurrences (all) | 1 / 463 (0.22%) 1 | 1 / 449 (0.22%) 1 | |
| Reproductive system and breast disorders Ovarian cyst subjects affected / exposed occurrences (all) | 1 / 463 (0.22%) 1 | 0 / 449 (0.00%) 0 | |
| Breast pain subjects affected / exposed occurrences (all) | 0 / 463 (0.00%) 0 | 1 / 449 (0.22%) 1 | |
| Respiratory, thoracic and mediastinal disorders Asthma subjects affected / exposed occurrences (all) | 1 / 463 (0.22%) 1 | 1 / 449 (0.22%) 1 | |
| Bronchospasm subjects affected / exposed occurrences (all) | 0 / 463 (0.00%) 0 | 2 / 449 (0.45%) 2 | |
| Dyspnoea subjects affected / exposed occurrences (all) | 0 / 463 (0.00%) 0 | 1 / 449 (0.22%) 1 | |
| Dysphonia subjects affected / exposed occurrences (all) | 1 / 463 (0.22%) 1 | 0 / 449 (0.00%) 0 | |
| Dry throat | | | |

| | | | |
|---------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Cough | | | |
| subjects affected / exposed | 2 / 463 (0.43%) | 2 / 449 (0.45%) | |
| occurrences (all) | 2 | 3 | |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 2 / 449 (0.45%) | |
| occurrences (all) | 0 | 2 | |
| Epistaxis | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 1 / 449 (0.22%) | |
| occurrences (all) | 1 | 1 | |
| Lower respiratory tract congestion | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences (all) | 0 | 1 | |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences (all) | 0 | 2 | |
| Nasal congestion | | | |
| subjects affected / exposed | 2 / 463 (0.43%) | 0 / 449 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Nasal discomfort | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 3 / 449 (0.67%) | |
| occurrences (all) | 1 | 3 | |
| Pulmonary arterial hypertension | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences (all) | 0 | 1 | |
| Throat irritation | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences (all) | 0 | 1 | |
| Psychiatric disorders | | | |
| Acute stress disorder | | | |

| | | | |
|--|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Depression | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Insomnia | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 1 / 449 (0.22%) | |
| occurrences (all) | 1 | 1 | |
| Restlessness | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 1 / 449 (0.22%) | |
| occurrences (all) | 1 | 1 | |
| Injury, poisoning and procedural complications | | | |
| Animal bite | | | |
| subjects affected / exposed | 2 / 463 (0.43%) | 0 / 449 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Arthropod bite | | | |
| subjects affected / exposed | 2 / 463 (0.43%) | 0 / 449 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Mallet finger | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Limb injury | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 1 / 449 (0.22%) | |
| occurrences (all) | 1 | 1 | |
| Joint dislocation | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Head injury | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Contusion | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 1 / 449 (0.22%) | |
| occurrences (all) | 1 | 1 | |
| Procedural pain | | | |

| | | | |
|---|---------------------------|---------------------------|--|
| subjects affected / exposed occurrences (all) | 2 / 463 (0.43%) 2 | 0 / 449 (0.00%) 0 | |
| Road traffic accident subjects affected / exposed occurrences (all) | 1 / 463 (0.22%) 1 | 0 / 449 (0.00%) 0 | |
| Cardiac disorders Palpitations subjects affected / exposed occurrences (all) | 1 / 463 (0.22%) 1 | 0 / 449 (0.00%) 0 | |
| Nervous system disorders Carotid artery stenosis subjects affected / exposed occurrences (all) | 1 / 463 (0.22%) 1 | 0 / 449 (0.00%) 0 | |
| Burning sensation subjects affected / exposed occurrences (all) | 0 / 463 (0.00%) 0 | 1 / 449 (0.22%) 1 | |
| Dizziness subjects affected / exposed occurrences (all) | 2 / 463 (0.43%) 2 | 3 / 449 (0.67%) 3 | |
| Hypoaesthesia subjects affected / exposed occurrences (all) | 1 / 463 (0.22%) 1 | 1 / 449 (0.22%) 1 | |
| Headache subjects affected / exposed occurrences (all) | 241 / 463 (52.05%) 376 | 206 / 449 (45.88%) 287 | |
| Dysgeusia subjects affected / exposed occurrences (all) | 1 / 463 (0.22%) 3 | 0 / 449 (0.00%) 0 | |
| Neuralgia subjects affected / exposed occurrences (all) | 0 / 463 (0.00%) 0 | 1 / 449 (0.22%) 1 | |
| VIth nerve paresis subjects affected / exposed occurrences (all) | 1 / 463 (0.22%) 1 | 0 / 449 (0.00%) 0 | |
| Trigeminal neuralgia | | | |

| | | | |
|---|----------------------|----------------------|--|
| subjects affected / exposed occurrences (all) | 0 / 463 (0.00%) 0 | 1 / 449 (0.22%) 1 | |
| Sciatica subjects affected / exposed occurrences (all) | 0 / 463 (0.00%) 0 | 1 / 449 (0.22%) 1 | |
| Paraesthesia subjects affected / exposed occurrences (all) | 0 / 463 (0.00%) 0 | 1 / 449 (0.22%) 1 | |
| Neuromuscular blockade subjects affected / exposed occurrences (all) | 1 / 463 (0.22%) 1 | 0 / 449 (0.00%) 0 | |
| Blood and lymphatic system disorders Lymphadenopathy subjects affected / exposed occurrences (all) | 1 / 463 (0.22%) 1 | 0 / 449 (0.00%) 0 | |
| Iron deficiency anaemia subjects affected / exposed occurrences (all) | 1 / 463 (0.22%) 1 | 0 / 449 (0.00%) 0 | |
| Pseudolymphoma subjects affected / exposed occurrences (all) | 1 / 463 (0.22%) 1 | 0 / 449 (0.00%) 0 | |
| Ear and labyrinth disorders Presbycusis subjects affected / exposed occurrences (all) | 0 / 463 (0.00%) 0 | 1 / 449 (0.22%) 1 | |
| Vertigo subjects affected / exposed occurrences (all) | 1 / 463 (0.22%) 1 | 0 / 449 (0.00%) 0 | |
| Eye disorders Ocular hyperaemia subjects affected / exposed occurrences (all) | 0 / 463 (0.00%) 0 | 1 / 449 (0.22%) 1 | |
| Retinal detachment subjects affected / exposed occurrences (all) | 1 / 463 (0.22%) 1 | 0 / 449 (0.00%) 0 | |
| Gastrointestinal disorders | | | |

| | | |
|----------------------------------|--------------------|--------------------|
| Abdominal pain | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) |
| occurrences (all) | 0 | 1 |
| Abdominal pain upper | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) |
| occurrences (all) | 1 | 0 |
| Aphthous ulcer | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) |
| occurrences (all) | 0 | 1 |
| Constipation | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) |
| occurrences (all) | 0 | 1 |
| Dyspepsia | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 3 / 449 (0.67%) |
| occurrences (all) | 0 | 3 |
| Diarrhoea | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 1 / 449 (0.22%) |
| occurrences (all) | 1 | 1 |
| Dental caries | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) |
| occurrences (all) | 0 | 1 |
| Hypoaesthesia oral | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) |
| occurrences (all) | 1 | 0 |
| Gastrooesophageal reflux disease | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 1 / 449 (0.22%) |
| occurrences (all) | 1 | 1 |
| Gastrointestinal disorder | | |
| subjects affected / exposed | 119 / 463 (25.70%) | 102 / 449 (22.72%) |
| occurrences (all) | 153 | 118 |
| Food poisoning | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) |
| occurrences (all) | 0 | 1 |
| Mouth haemorrhage | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) |
| occurrences (all) | 0 | 1 |

| | | | |
|--|-----------------|-----------------|--|
| Enteritis | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Nausea | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences (all) | 0 | 1 | |
| Rectal fissure | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Tongue eruption | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Skin and subcutaneous tissue disorders | | | |
| Acne | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 1 / 449 (0.22%) | |
| occurrences (all) | 1 | 1 | |
| Dermatitis | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 1 / 449 (0.22%) | |
| occurrences (all) | 1 | 1 | |
| Alopecia | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Eczema | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Night sweats | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences (all) | 0 | 1 | |
| Hyperhidrosis | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 2 / 449 (0.45%) | |
| occurrences (all) | 0 | 2 | |
| Erythema | | | |
| subjects affected / exposed | 4 / 463 (0.86%) | 6 / 449 (1.34%) | |
| occurrences (all) | 6 | 7 | |
| Peau d'orange | | | |

| | | | |
|---|-----------------------|----------------------|--|
| subjects affected / exposed occurrences (all) | 1 / 463 (0.22%) 1 | 0 / 449 (0.00%) 0 | |
| Pruritus subjects affected / exposed occurrences (all) | 2 / 463 (0.43%) 2 | 2 / 449 (0.45%) 3 | |
| Rash subjects affected / exposed occurrences (all) | 2 / 463 (0.43%) 2 | 1 / 449 (0.22%) 1 | |
| Rash erythematous subjects affected / exposed occurrences (all) | 1 / 463 (0.22%) 1 | 0 / 449 (0.00%) 0 | |
| Renal and urinary disorders Nephrolithiasis subjects affected / exposed occurrences (all) | 0 / 463 (0.00%) 0 | 1 / 449 (0.22%) 1 | |
| Haematuria subjects affected / exposed occurrences (all) | 1 / 463 (0.22%) 1 | 0 / 449 (0.00%) 0 | |
| Urinary retention subjects affected / exposed occurrences (all) | 1 / 463 (0.22%) 1 | 0 / 449 (0.00%) 0 | |
| Endocrine disorders Autoimmune thyroiditis subjects affected / exposed occurrences (all) | 0 / 463 (0.00%) 0 | 1 / 449 (0.22%) 1 | |
| Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all) | 8 / 463 (1.73%) 10 | 5 / 449 (1.11%) 6 | |
| Flank pain subjects affected / exposed occurrences (all) | 0 / 463 (0.00%) 0 | 1 / 449 (0.22%) 1 | |
| Bursitis subjects affected / exposed occurrences (all) | 2 / 463 (0.43%) 2 | 0 / 449 (0.00%) 0 | |
| Back pain | | | |

| | | |
|--------------------------------|--------------------|--------------------|
| subjects affected / exposed | 1 / 463 (0.22%) | 1 / 449 (0.22%) |
| occurrences (all) | 1 | 1 |
| Axillary mass | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) |
| occurrences (all) | 1 | 0 |
| Arthritis | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) |
| occurrences (all) | 0 | 1 |
| Intervertebral disc protrusion | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) |
| occurrences (all) | 1 | 0 |
| Limb discomfort | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) |
| occurrences (all) | 0 | 1 |
| Joint swelling | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) |
| occurrences (all) | 1 | 0 |
| Musculoskeletal stiffness | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 2 / 449 (0.45%) |
| occurrences (all) | 0 | 2 |
| Myalgia | | |
| subjects affected / exposed | 284 / 463 (61.34%) | 260 / 449 (57.91%) |
| occurrences (all) | 501 | 373 |
| Neck pain | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) |
| occurrences (all) | 0 | 1 |
| Osteoarthritis | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) |
| occurrences (all) | 1 | 0 |
| Plantar fasciitis | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) |
| occurrences (all) | 1 | 0 |
| Pain in extremity | | |
| subjects affected / exposed | 3 / 463 (0.65%) | 4 / 449 (0.89%) |
| occurrences (all) | 3 | 5 |
| Synovial cyst | | |

| | | | |
|-----------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Tendon disorder | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Infections and infestations | | | |
| Anal abscess | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Bronchitis | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 5 / 449 (1.11%) | |
| occurrences (all) | 1 | 5 | |
| Cystitis | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Ear infection | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Erysipelas | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Fungal infection | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Fungal skin infection | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences (all) | 0 | 1 | |
| Gastroenteritis | | | |
| subjects affected / exposed | 3 / 463 (0.65%) | 0 / 449 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| Herpes simplex | | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Genital infection fungal | | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) | |
| occurrences (all) | 0 | 1 | |

| | | |
|-----------------------------------|-----------------|-----------------|
| Impetigo | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) |
| occurrences (all) | 0 | 1 |
| Injection site cellulitis | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 2 / 449 (0.45%) |
| occurrences (all) | 0 | 2 |
| Influenza | | |
| subjects affected / exposed | 3 / 463 (0.65%) | 2 / 449 (0.45%) |
| occurrences (all) | 3 | 2 |
| Infection | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) |
| occurrences (all) | 1 | 0 |
| Otitis externa | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) |
| occurrences (all) | 0 | 1 |
| Oral herpes | | |
| subjects affected / exposed | 2 / 463 (0.43%) | 1 / 449 (0.22%) |
| occurrences (all) | 2 | 1 |
| Nasopharyngitis | | |
| subjects affected / exposed | 7 / 463 (1.51%) | 3 / 449 (0.67%) |
| occurrences (all) | 7 | 3 |
| Lower respiratory tract infection | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) |
| occurrences (all) | 0 | 1 |
| Laryngitis | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 1 / 449 (0.22%) |
| occurrences (all) | 1 | 1 |
| Pneumonia | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 2 / 449 (0.45%) |
| occurrences (all) | 0 | 2 |
| Pulpitis dental | | |
| subjects affected / exposed | 1 / 463 (0.22%) | 0 / 449 (0.00%) |
| occurrences (all) | 1 | 0 |
| Rash pustular | | |
| subjects affected / exposed | 0 / 463 (0.00%) | 1 / 449 (0.22%) |
| occurrences (all) | 0 | 1 |

| | | | |
|---|----------------------|----------------------|--|
| Pharyngitis streptococcal subjects affected / exposed occurrences (all) | 0 / 463 (0.00%) 0 | 1 / 449 (0.22%) 1 | |
| Sinusitis subjects affected / exposed occurrences (all) | 4 / 463 (0.86%) 4 | 0 / 449 (0.00%) 0 | |
| Otitis media subjects affected / exposed occurrences (all) | 1 / 463 (0.22%) 1 | 0 / 449 (0.00%) 0 | |
| Upper respiratory tract infection subjects affected / exposed occurrences (all) | 7 / 463 (1.51%) 7 | 4 / 449 (0.89%) 4 | |
| Urinary tract infection subjects affected / exposed occurrences (all) | 2 / 463 (0.43%) 2 | 0 / 449 (0.00%) 0 | |
| Viral upper respiratory tract infection subjects affected / exposed occurrences (all) | 4 / 463 (0.86%) 4 | 1 / 449 (0.22%) 1 | |
| Vulvovaginal mycotic infection subjects affected / exposed occurrences (all) | 1 / 463 (0.22%) 1 | 0 / 449 (0.00%) 0 | |
| Metabolism and nutrition disorders | | | |
| Decreased appetite subjects affected / exposed occurrences (all) | 0 / 463 (0.00%) 0 | 1 / 449 (0.22%) 1 | |
| Dyslipidaemia subjects affected / exposed occurrences (all) | 0 / 463 (0.00%) 0 | 2 / 449 (0.45%) 2 | |
| Type 2 diabetes mellitus subjects affected / exposed occurrences (all) | 0 / 463 (0.00%) 0 | 1 / 449 (0.22%) 1 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-----------------|---|
| 30 October 2017 | <ul style="list-style-type: none">Following the initial approval of the GlaxoSmithKline (GSK) Biologicals' HZ/su vaccine, this protocol was amended to indicate that the Trademark is Shingrix. In addition, the term "candidate" vaccine has been replaced by "study" vaccine throughout the protocol and the term "investigational" vaccine has been replaced by "study" vaccine. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported